Tissue specific prodrugs
The invention provides novel peptide prodrugs which contain cleavage sites specifically cleaved by prostate specific membrane antigen (PSMA). These prodrugs are useful for substantially inhibiting the non-specific toxicity of a variety of therapeutic drugs. PSMA is secreted by prostatic glandular cells. Upon cleavage of the prodrug by PSMA, the therapeutic drugs are activated and exert their toxicity. Sesquiterpene-γ-lactones form part of the prodrugs, and are designed to be linked to carrier moieties such as the peptides of the invention. Methods for treating cell proliferative disorders are also featured in the invention.
1. A method of treating a PSMA-producing cell proliferation disorder selected from prostate cancer, breast cancer, renal cancer, colon cancer, pancreatic cancer, melanoma cancer, lung cancer, and testicular cancer, the method comprising administering to a subject in need thereof a composition comprising a therapeutically effective amount of 8-0-debutanoylthapsigargin (12ADT) linked to the aspartic acid of a peptide having the sequence Asp-Glu*Glu*Glu*Glu, wherein at least one of the bonds designated with * is a gamma carboxy linkage.
2. The method of claim 1 , wherein the PSMA-producing cell proliferation disorder is prostate cancer.
3. The method of claim 1 , wherein the PSMA-producing cell proliferation disorder is breast cancer.
4. The method of claim 1 , wherein the composition is administered parenterally by injection or by gradual infusion over time.
5. The method of claim 1 , wherein the composition is administered intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, or transdermally.
6. The method of claim 1 , wherein the PSMA-producing cell proliferation disorder is renal cancer.
7. The method of claim 1 , wherein the PSMA-producing cell proliferation disorder is colon cancer.
8. The method of claim 1 , wherein the PSMA-producing cell proliferation disorder is pancreatic cancer.
9. The method of claim 1 , wherein the PSMA-producing cell proliferation disorder is testicular cancer.
10. The method of claim 1 , wherein the PSMA-producing cell proliferation disorder is lung cancer.
11. The method of claim 1 , wherein the PSMA-producing cell proliferation disorder is melanoma cancer.